Skip to content
Biodatica
Start free

Baptist Health South Florida

Miami, Florida

Oncologygene therapyPhase III
Compare Sign in to watch

What changed

NIH R01 · $0.7M · Quantitative imaging phenotypic classifier for distinguishing radiation effects from tumor recurrence in Glioblastoma

6w agoGrant renewalJun 4, 2026Source filing (opens the source filing in a new tab)

Momentum

83no change

Momentum 83 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

349 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Jun 1, 2026

    Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer, Cancer Metastatic · NOT_YET_RECRUITING · sponsor: Baptist Health South Florida · Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

    ClinicalTrials.gov · NCT07454668 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Dec 3, 2025

    Glioblastoma, Brain Cancer, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma · RECRUITING · sponsor: Baptist Health South Florida · Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

    ClinicalTrials.gov · NCT06991101 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Jan 29, 2024

    Brain Metastases, HER2-positive Breast Cancer · TERMINATED · sponsor: Baptist Health South Florida · Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

    ClinicalTrials.gov · NCT05553522 (opens the source filing in a new tab)

  4. Grant

    R01 · $710k · non-dilutive

    Jun 30, 2022

    UNIVERSITY OF WISCONSIN-MADISON · PI TIWARI, PALLAVI · NCI · award ends May 31, 2028 · Quantitative imaging phenotypic classifier for distinguishing radiation effects from tumor recurrence in Glioblastoma

    NIH RePORTER · NIH RePORTER 11377043 (opens the source filing in a new tab)

  5. Trial

    PHASE2/PHASE3 registered

    Jan 31, 2020

    Anaplastic Astrocytoma, Glioblastoma, Oligodendroglioma, Supratentorial Glioblastoma · WITHDRAWN · sponsor: NRG Oncology · Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

    ClinicalTrials.gov · NCT04105374 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources